Overview

11ß-HSD1 and Metabolic Syndrome

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the insulin sensitizing effects of rosiglitazone were accompanied by changes in 11ß-HSD1 expression and activity in different tissues. Furthermore the metabolic and hormonal effects of PPAR gamma stimulation by rosiglitazone will be analysed in several tissues.
Phase:
Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Treatments:
Rosiglitazone